Differences in risk factors of malignancy between men and women with type 2 diabetes: A retrospective case-control study

Dąbrowski, Mariusz; Szymańska‐Garbacz, Elektra; Miszczyszyn, Zofia; Dereziński, Tadeusz; Czupryniak, Leszek

doi:10.18632/oncotarget.17716

Cited by 3 publications

(4 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first clinical reports indicating the protective effect of metformin in terms of cancer incidence and cancer death risk appeared in the middle of the first decade of this century [72,73]. Own studies also confirmed protective effect of metformin in the Polish population, irrespective of gender [74,75]. In numerous meta-analyses of case-control and cohort studies, metformin use was associated with 10-40% reduction of cancer incidence and mortality, which was summarized by Heckman-Stoddard et al in their paper [76].…”

Section: Metforminmentioning

confidence: 90%

“…The first observational studies seemed to confirm this relationship [ 72 , 73 , 86 ], although there were differences between individual formulations [ 87 ]. Own observation, as well as the largest systematic review, did not show an increased risk of cancer associated with the use vs. non-use of sulfonylureas [ 74 , 75 , 88 ].…”

Section: Antidiabetic Medications and Cancermentioning

confidence: 99%

See 1 more Smart Citation

Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors

Dąbrowski

2021

IJMS

Self Cite

View full text Add to dashboard Cite

In the last decade, cancer became the leading cause of death in the population under 65 in the European Union. Diabetes is also considered as a factor increasing risk of cancer incidence and mortality. Type 2 diabetes is frequently associated with being overweight and obese, which also plays a role in malignancy. Among biological mechanisms linking diabetes and obesity with cancer hyperglycemia, hyperinsulinemia, insulin resistance, increased levels of growth factors, steroid and peptide hormones, oxidative stress and increased activity of pro-inflammatory cytokines are listed. Antidiabetic medications can modulate cancer risk through directly impacting metabolism of cancer cells as well as indirectly through impact on risk factors of malignancy. Some of them are considered beneficial (metformin and thiazolidinedions—with the exception of bladder cancer); on the other hand, excess of exogenous insulin may be potentially harmful, while other medications seem to have neutral impact on cancer risk. Inhibitors of the sodium-glucose cotransporter-2 (SGLT-2) are increasingly used in the treatment of type 2 diabetes. However, their association with cancer risk is unclear. The aim of this review was to analyze the anticancer potential of this class of drugs, as well as risks of site-specific malignancies associated with their use.

show abstract

Section: Metforminmentioning

confidence: 90%

Section: Antidiabetic Medications and Cancermentioning

confidence: 99%

Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors

Dąbrowski

2021

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…Previous studies indicated that there are significant differences of cardiovascular disease incidence in gender and age. [17][18][19] Estrogen protection against NRVHD may contribute to a lower risk in NRVHD in premenopausal women than age-matched men. 20 This study also assessed the risk factors of NRVHD.…”

Section: Discussionmentioning

confidence: 99%

“…The incident cases in any year were higher for females than for males; in 2019, they were 0.90 million (95% UI = 0.85 to 0.95 million), respectively, for females, and 0.76 million (95% UI = 0.70 to 0.81 million) for males. The age-standardized incidence rate (ASIR) increased slightly from 1990 to 2019 (EAPC = 0.39, 95% UI = 0.29 to 0.49), being 18 The ASIR in any year was also higher for females than for males.…”

Section: Global and Regional Incidence Of Non-rheumatic Valvular Hear...mentioning

confidence: 99%

Global, regional, and national incidence, mortality, and disability-adjusted life years of non-rheumatic valvular heart disease and trend analysis from 1990 to 2019: Results from the Global Burden of Disease study 2019

Wang,

Geng,

Shen

et al. 2023

Asian Cardiovasc Thorac Ann

View full text Add to dashboard Cite

Background In the context of the population growing and aging worldwide, the incidence of non-rheumatic valvular heart disease increased rapidly. This study aimed to describe the burden of non-rheumatic valvular heart disease, providing an up-to-date and comprehensive analysis on the global and regional levels and time trends from 1900 to 2019. Methods The Global Burden of Disease 2019 was used to obtain data for this analysis. Non-rheumatic valvular heart disease in the Global Burden of Disease study includes both non-rheumatic calcific aortic valve disease and non-rheumatic degenerative mitral valve disease. The incidence, mortality, and disability-adjusted life year in 204 countries from 1990 to 2019 were analyzed by location, year, sex, age, and socio-demographic index. Estimated annual percentage change was calculated to represent the temporal trends from 1990 to 2019. Spearman's rank order correlation was used to determine the correlation between socio-demographic index and the incidence and burden of non-rheumatic valvular heart disease. Results Globally, there were 1.65 million (95% uncertainty interval, 1.56–1.76 million) incident cases, 0.16 million (95% uncertainty interval, 0.14–0.18 million) death cases, and 2.79 million (95% uncertainty interval, 2.52–3.31 million) disability-adjusted life years of non-rheumatic valvular heart disease. Compared with 1990, the number of incident cases, death cases, and disability-adjusted life years in 2019 increased by 104.58%, 210.60%, and 167.62%, respectively, the age-standardized incidence rate (estimated annual percentage change, 0.39; 95% confidence interval, 0.29 to 0.49) increased due to population growth, and the age-standardized death rates (estimated annual percentage change, −0.32; 95% confidence interval, −0.39 to −0.25) and age-standardized disability-adjusted life year rate (estimated annual percentage change, −0.81; 95% confidence interval, −0.87 to −0.74) decreased during this period. Regarding the socio-demographic index, the highest age-standardized incidence, death, and disability-adjusted life year rates of non-rheumatic valvular heart disease were found in high-socio-demographic index countries in 2019. Meantime, the age-standardized incidence rate remained increased from 1990 to 2019, while significant decreases were found in the age-standardized death rate and age-standardized disability-adjusted life year rate. Females have higher age-standardized incidence rate, while higher age-standardized death rate and age-standardized disability-adjusted life year rate belong to males globally during the period of 1990–2019. Increasing trends were observed for both incidence, death, and disability-adjusted life year rates with age. High systolic blood pressure was the leading cause for non-rheumatic valvular heart disease across all ages. Conclusions From 1990 to 2019, the age-standardized incidence rate of non-rheumatic valvular heart disease remained increased, while age-standardized death rate and age-standardized disability-adjusted life year rate decreased, resulting from the growing population worldwide and improving medical resources. The aged, who has high systolic blood pressure and diet high in sodium, should pay more attention to, especially in high-socio-demographic index regions. With the population aging, the number of patients who require heart valve replacement is estimated to increase significantly in the future. Effective measures are warranted to control and treat the incidence and burden of non-rheumatic valvular heart disease.

show abstract

Insulin and Other Hypoglycemic Drugs

Schalliol¹,

Pittman²,

Ray³

2018

Side Effects of Drugs Annual

View full text Add to dashboard Cite

Differences in risk factors of malignancy between men and women with type 2 diabetes: A retrospective case-control study

Cited by 3 publications

References 52 publications

Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors

Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors

Global, regional, and national incidence, mortality, and disability-adjusted life years of non-rheumatic valvular heart disease and trend analysis from 1990 to 2019: Results from the Global Burden of Disease study 2019

Insulin and Other Hypoglycemic Drugs

Contact Info

Product

Resources

About